1. Introduction {#s0005}
===============

Southern Africa is remarkably rich in plant diversity with approximately 30 000 flowering plant species which equates to nearly 10% of the higher plants globally ([@bib100]). Plants have been used medicinally for centuries and the medicinal plant trade is still prominent today. According to the World Health Organization (WHO), up to 80% of people living on the African continent, equating to more than a half billion people, use traditional medicines to meet their primary health care needs. Nonetheless, the industry is not yet exploited to its full capacity. In South Africa, for example, around 3 000 medicinal plant species are frequently used in plant-based medicines, however less than 40 indigenous species have been commercialized to some degree ([@bib99]).

The statistics on HIV in the southern African region emphasizes its devastating effects. In 2015, there were 36.7 million people living with HIV. Worldwide, 2.1 million people became newly infected with HIV (UNAIDS, 2016). In 2012, sub-Saharan Africa accounted for 70% of all people newly infected with HIV and 71% of all people living with HIV (UNAIDS, 2013). Collectively eastern and southern Africa are home to 6% of the global population, but accounted for 52% of all people living with HIV and nearly half the approximated 2.3 million people who became infected with HIV in 2012 (UNAIDS, 2013).

Anti-retroviral therapy (ART) is an effective treatment for people living with HIV. The standard treatment seeks to suppress the HIV replication cycle and halt disease progression. Antiretroviral therapy is significant in improving the life of people living with HIV, however the drugs have many disadvantages, including resistance, toxicity, limited availability, and lack of curative effect ([@bib17]). The potential of HIV becoming resistant to anti-retroviral (ARV) treatment has become an increasing concern since it was first reported decades ago (De Clercq, 1995). As pathogens become drug resistant, the need for development of new medicines is being realized all over the world. These shortcomings open avenues for the use of natural products in the management of HIV/AIDS.

2. Methodology {#s0010}
==============

Electronic searches of Science Direct, PubMed central and Google Scholar were undertaken with search terms "HIV", "medicinal plants", "Africa", "anti-viral" and "southern Africa". Initially publication titles were screened for suitability and plant species, active compounds and their mode of action were documented from primary literature sources. Ethnobotanical surveys in other African countries such as Ethiopia ([@bib5]), Uganda ([@bib53]), Cameroon ([@bib65]), Zimbabwe ([@bib104]), Namibia (Chinsembu and Hedimbi, 2010) and Zambia (Chinsembu, 2016) also assisted in identifying plants traditionally used for management of HIV or HIV symptoms. The inclusion criteria were: (1) plants should have a record of traditional/popular use for infectious or viral diseases, HIV treatment or symptoms similar to HIV infection, (2) if not traditionally/popularly used, plants should be closely related to plants with popular use and HIV activity identified by means of in vitro assays, (3) plants should have been identified scientifically, (4) should be native to the southern African region and (5) anti-HIV activity should be within acceptable ranges. Clinical relevant concentrations have been defined as IC~50~ of\<50 or\<100 µg/ml for extracts and at\<5 or\<25 µM for individual compounds and have been applied as a selection criterion in this study ([@bib1]; Butterweck and Nahrstedt, 2012; [@bib24]; Gertsch, 2009). Since traditional refers to plants with a long history of use, and HIV being a relatively new disease, the use of these plants are referred to as "popular" or "popularly used" against HIV.

3. Screening methods for anti-HIV activity in medicinal plants {#s0015}
==============================================================

Many plants have been traditionally used to treat viral infections and other ailments. Investigation of these claims led to the discovery of numerous plant derived anti-HIV compounds which are widely distributed in nature ([@bib88]). Therefore, screening medicinal plants provides an opportunity for the discovery of HIV inhibitors with lower or no toxicity and/or side effects ([@bib76]). Biologically active substances harvested from plants, can be found in any organ of the plant, although leaf material is most traditionally used ([@bib76]).

Various laboratory based investigations have been conducted using plant extracts and isolated compounds employing a variety of assays. Most of the tests are performed on the enzymes reverse transcriptase (RT), integrase (IN) and protease (PR), proteins involved in activation of viral genes or cells that are infected with viruses or pseudoviruses, and the activity determined by an indicator such as MTT or luciferase activity. The MTT assays are based on the reduction of the yellow coloured 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by mitochondrial dehydrogenases of metabolically active cells. In metabolically active cells, blue formazan is produced which is measured spectrophotometrically to indicate cell viability in assays of cell proliferation and cytotoxicity ([@bib23]; [@bib87]). These targets aim to determine the inhibition or reduction of viral infection on various levels, and present various advantages and disadvantages to be considered in evaluating anti-viral activity ( [Table 1](#t0005){ref-type="table"}).Table 1A summary of the most popular anti-HIV assays presenting the advantages and disadvantages of each assay.Table 1AssayTargetAdvantagesDisadvantagesReferenceHIV-1 Reverse Transcriptase (RT) assayReverse Transcriptase is an enzyme that converts the viral RNA genome to viral DNA.The assay kits can be acquired from various companies.False positives due to unspecific binding of plant compounds such as tannins to proteins and inhibit RT. RT uses magnesium or manganese divalent ions as co-factors. The presence of palladium and iron is known to induce irreversible inhibition of RT. Sulfated polysaccharides show anti-HIV activity with aqueous extracts by destabilizing the glycoprotein complex and/or inhibiting reverse transcriptase.([@bib9], [@bib11], [@bib19], [@bib21], [@bib29], [@bib33], [@bib46], [@bib50], [@bib97], [@bib106]).HIV-1 Integrase (IN) assayIntegrase enzyme is required for the integration of the synthesized viral double stranded DNA into the chromosome in the nucleus.The Xpress HIV-1 IN Assay Kit can be acquired from various companies.False positives obtained due to unspecific binding of plant compounds to proteins.([@bib9], [@bib43], [@bib50], [@bib106])HIV-1 Protease (PR) assayProtease enzyme cleaves viral polyproteins into structural and functional components which are assembled to form progeny virions.Assay kits such as the HIV-II PR HIV-FRET (fluorescence resonance energy transfer) and the recombinant HIV-1 protease solution can be acquired from various companies.False positives can be obtained due to unspecific binding of plant compounds to proteins.([@bib9], [@bib38], [@bib43], [@bib46], [@bib50], [@bib106]).HIV-1 p24 assayIt is an enzyme-linked immunosorbent assay used to detect and quantify HIV-1 p24 core protein. HIV-1 inhibition is determined by a decrease in viral p24 antigen levels measuring absorbance at 450 nm.The antigen assay kit can be acquired from various companies.False positives can be obtained due to unspecific binding of plant compounds to proteins.([@bib50]).Cell based assays infected with isolated HIV strains or pseudovirionsHIV cell cultures are maintained and added to cells containing plant extracts and compounds. The activity is measured using the MTT assay. Cells infected with a recombinant virus is obtained by the transfection of a plasmid containing the luciferase gene and luciferase activity is measured.The assay does not rely on inhibition of a single enzyme, and more targets can be tested using a virus or pseudovirion transfection.Constituents with antioxidant activity result in too high MTT activity as it is a redox-based assay. Free thiols lead to the reduction of MTT to the formazon product and therefore inaccurate results are obtained. Plant compounds such as (iso) flavonoids, stabilize the firefly luciferase reporter enzyme increasing the bioluminescent signal, probably due to the direct interaction of the compounds with the firefly luciferase reporter enzyme thereby increasing its half-life and stabilizing the enzyme activity. Compounds stabilizing the firefly luciferase reporter protein give false positives.([@bib7], [@bib23], [@bib78], [@bib82], [@bib87], [@bib90], [@bib106])NF-κB activation assayCells are stably transfected with a plasmid containing the firefly luciferase gene driven by the HIV-LTRpromoter, highly dependent on NF-κB activation induced by TNFα. High expression of luciferase activity reflects NF-κB activation through the canonical pathway.Plant-derived antiviral compounds interfering with HIV-1 LTR promoter regulatory proteins are unlikely to generate drug-resistant HIV strains.Plant compounds such as (iso) flavonoids, stabilize the firefly luciferase reporter enzyme increasing the bioluminescent signal, probably due to the direct interaction of the compounds with the firefly luciferase reporter enzyme thereby increasing its half-life and stabilizing the enzyme activity. Compounds stabilizing the firefly luciferase reporter protein give false positives.([@bib7], [@bib90], [@bib98])Hela-Tat-Luc assayThe Hela-Tat-Luc cells are stably transfected with the plasmid pcDNA3-TAT together with a reporter plasmid LTR-Luc. HIV-1 LTR is highly activated in this cell line as a consequence of high levels of intracellular Tat protein.Plant-derived antiviral compounds interfering with HIV-1 LTR promoter regulatory proteins are unlikely to generate drug-resistant HIV strains.Plant compounds such as (iso) flavonoids, stabilize the firefly luciferase reporter enzyme increasing the bioluminescent signal, probably due to the direct interaction of the compounds with the firefly luciferase reporter enzyme thereby increasing its half-life and stabilizing the enzyme activity.([@bib7], [@bib90], [@bib98])Hela-Tet-ON-Luc assayExtracts active in both NF-κB (\>50% inhibition) and Tat (\>30% inhibition) assays, evaluated by Hela-Tet-ON assay to discard nonspecific luciferase inhibitory activity.Plant-derived antiviral compounds interfering with HIV-1 LTR promoter regulatory proteins are unlikely to generate drug-resistant HIV strains. Eliminate the nonspecific luciferase activity.([@bib7], [@bib90], [@bib98])

RT converts the viral RNA genome to viral DNA using its polymerase domain (RNA dependent DNA polymerase activity), while the ribonuclease H (RNase H) domain degrades the RNA component from the intermediary RNA/DNA complex. The enzyme also has a DNA-dependent DNA polymerase function and most clinically available RT drugs, therefore target this enzyme. Numerous studies focused on the HIV-1 RT enzyme and various protocols have been employed measuring ethyl-3H thymidine triphosphate (3H TTP) by RT using polyadenylic acid-oligodeoxythymidilic acid (polyA-oligodT) as template primer in the presence and absence of a test substance such as isolated compounds or plant extracts ([@bib3], [@bib10]). Various kits are used for determining the inhibition of enzymes and viral components such as the Capture ELISA kit (GenxBio Health Science, India) ([@bib16]) and HIV-RT colourimetric enzyme-linked-immunosorbent serologic assay (ELISA) kit obtained from Roche Diagnostics, Mannheim, Germany ([@bib19], [@bib29], [@bib46], [@bib50], [@bib97], [@bib106]) or a purified recombinant HIV-1 RT enzyme (Merck, Darmstadt, Germany) ([@bib46]). Several interactions and measures have been identified to optimise the assay conditions. It has been found that HIV-1 RT uses magnesium or manganese divalent ions as a co-factor ([@bib11]) and that palladium and iron might also affect the assay as they are responsible for irreversible inhibition of RT and subsequent reduction in virus proliferation ([@bib33]). Since ions of various metals are accumulated by plants and therefore present in plant extracts, these ions may be present in and might affect the outcomes. Most methodologies describing the inhibition of HIV-1 RT by crude plant extracts do not take into consideration the effect of metal ions in regulating the activity of HIV-1 RT ([@bib9]). Consequently, it would be important to determine metal ions in plant extracts prior to screening in order to avoid false inhibitory observations at the screening stage.

IN, in conjunction with accessory viral proteins, is required for the integration of the synthesized viral double stranded DNA into the chromosome in the nucleus of the host cell. The HIV-1 integrase (HIV-1 IN) enzyme has also been employed on extracts and compounds such as catechins in various studies using the Xpress HIV-1 IN Assay Kit (Express Biotech International, USA) or in an in vitro model ([@bib43]). A recombinant HIV-1 IN of *E. coli* origin ([@bib106]) and the evaluation against the 3' processing activity of HIV-1 IN have been performed on extracts and compounds ([@bib10]). The unspecific binding of plant compounds to proteins is, however, mostly not considered.

PR cleaves viral polyproteins into structural and functional components which are assembled to form progeny virions ([@bib9]). The protease enzyme has also been investigated in various assays such as the fluorometric detection of HIV-PR activity using HIV-II PR HIV-FRET (fluorescence resonance energy transfer) (AnaSpec Inc., USA) and a recombinant HIV-1 protease solution (Bachem, Switzerland). The glycohydrolase enzymes are found in the eukaryotic host cell\'s Golgi apparatus and are responsible for glycosylation of proteins. Inhibition of the glycohydrolase enzymes decreases the infectivity of the HIV virion, as the HIV envelope proteins are highly glycosylated during the life cycle of the virus. Glucosidase was found to be partly responsible for the glycosylation of HIV gp120 ([@bib38], [@bib46], [@bib50]). *Escherichia coli* expressing recombinant HIV-1 PR has also been used to detect the inhibitory effects of samples on HIV-1 PR by observing the bacterial growth curve ([@bib43], [@bib106]).

An ELISA kit (another enzyme-linked immunosorbent assay) is also available to detect and quantify HIV-1 p24 core protein using the HIV-1 p24 Antigen Assay kit (Beckman Coulter, Miami, FL, USA) ([@bib50]) and can be distinguished from the cell based assays. Cell based assays are commonly used with various different cell types and viruses. The CXCR4-tropic (NL4-3) or CCR5-tropic (NL-AD87) wild-type reference viruses ([@bib57]) and HIV-1c binding and entry assay on PBMCs have been described ([@bib55]). The utilised format "iFIGS" (Infection format of "Fusion-induced gene stimulation") represents an in vitro infection system in human HeLa cells. Thereby, upon infection with HIV, the reporter gene will be induced in a quantifiable fashion as beta galactosidase allows quantification of inhibitory effects of compounds or extracts ([@bib58]). HIV-1 pseudovirions and viruses has been used ([@bib78], [@bib82], [@bib106]) and Hela-Tat-Luc cells that are stably transfected with for instance a plasmid pcDNA3-TAT together with a reporter plasmid LTR-Luc indicates protein activation. Therefore the HIV-1 LTR is highly activated in this cell line as a consequence of high levels of intracellular Tat protein ([@bib98]). Isolated HIV strains (strain HTLV-IIIB/LAI) obtained from the culture supernatant of a HIV-infected HUT-78 cell line have been tested and cell viability was evaluated using the MTT assay ([@bib23]). African green monkey kidney cells (Vero) have also been used (Dang et al., 2011) and linked to cytotoxicity assays on MT-4 cells ([@bib61], [@bib62]).

Even though the MTT assay is generally applied to determine cell viability in in vitro assays, very little or no consideration is given to the possibility of constituents with antioxidant potential that result in extremely high MTT readings, and might provide false positive results. The stabilization of the luciferase gene is also often not considered, even though many plant components might provide false positive results ([@bib7], [@bib90]). The cytotoxicity of extracts and compounds are often also neglected and therefore the Selectivity Index (SI) which is achieved by dividing the cytotoxic concentration (CC~50~) by the effective inhibitory concentration (EC~50~) or Therapeutic Index (TI) which is achieved by dividing the cytotoxic concentration (CC~50~) by the non-cytotoxic concentration that inhibits/protects 50% uninfected cells (ID~50)~, are not reported. A value of more than 1 is indicative of an extract that is selective in inhibition and not only toxic to both the virus and the cells ([@bib23]).

In vitro assays have an important role in determining anti-HIV activity, mindful of the pitfalls and false positives that might arise from compounds in plant crude extracts. The lack of absorption, distribution, metabolism and excretion (ADME) characteristics and the lack of direct correlation with in vivo/clinical doses, limit the scope of application of in vitro bioassays and add to the challenges faced by in vitro screening ([@bib1]). It is often inaccurate to relate in vitro results from enzyme or protein inhibition assays to the in vivo situation, and these should be considered in screening of botanicals and botanical preparations. The hydrolysis and phase-II transformation of compounds within the in vivo system contribute to the incompatibility of in vitro results to the in vivo situation. Hydrolysis of flavonoids may result in formation of non-conjugated analogues able to induce a specific biological response to an even larger extent than the non-hydrolysed extract. Hydrolysis will also provide a site for conjugation which will result in excretion of the conjugate in the urine and the bile ([@bib25]). The type of flavonoid, the position and nature of the sugar may also affect the metabolism in the intestine and passing to the large intestine for absorption there ([@bib8], [@bib42]). Once the aglycone is absorbed it is quickly metabolised to form phase-II conjugates, mostly sulphates and glucuronides or O-methylation, which have a major impact on their activity as well as the ability of the body to excrete compounds ([@bib8], [@bib42]). These phase-II conjugates, obviously are not representative of the compounds in the original plant extract or botanical preparation anymore, and challenge the results obtained from in vitro assays. Well-known flavonoids such as kaempferol, apigenin and galangin are only present in low concentrations in plasma as they are nearly exclusively present as conjugated glucuronides in the systemic circulation after phase-II biotransformation ([@bib8], [@bib14], [@bib42]). Quercetin is often reported in anti-viral assays and is known for its specific absorption and hydrolysis patterns. Quercetin glucoside is absorbed in the small intestine, whereas quercetin rutinoside is absorbed from the colon after deglycosylation ([@bib42]). Caffeic acid and ferulic acid, also well-known anti-viral compounds are examples of compounds subjected to transformation, both metabolised to glucuronides although not very effectively ([@bib91]). No glucuronides have, however, been observed for chlorogenic acid and anthocyanidin glycosides which are rapidly absorbed and able to withstand deglycosylation reactions in humans ([@bib42]).

It is therefore important to consider the factors of transformation and conjugation of compounds in the intestines. Transformation of these compounds during absorption, or transformation by the liver in the human body affect the extrapolation of in vitro results to the in vivo situation. ADME characteristics for many compounds are not available, and therefore in vitro assays based on enzymes and cell based assays with protein targets are useful in screening and aims to link the traditional use of plants to activity. In vitro to in vivo extrapolation is however very complex, with more information needed to determine the in vivo situation for compounds from a botanical preparation with numerous compounds possibly being active components.

4. Anti-HIV activity of medicinal plant compounds {#s0020}
=================================================

A number of medicinal plants have been reported to have anti-HIV properties ([@bib17], [@bib23], [@bib89]). The structural diversity and adaptation ability to various environmental conditions have resulted in development of a range of defense compounds with various biological activities, therefore plant secondary metabolites represent a huge source for novel anti-HIV drugs that may be functional against HIV. Guided fractionation of these crude extracts has provided a platform for the discovery of novel and known anti-HIV compounds. With the emergence of drug resistant HIV variants in patients receiving ARV treatment, the search for novel effective inhibitors of HIV has accelerated. A condensed summary of some of the most active and most studied classes of plants compounds are provided in [Table 2](#t0010){ref-type="table"}.Table 2A summary of important compound groups with examples with strong anti-HIV activity.Table 2**Compound groupExampleMode of actionSpecies/ FamilyReference**AlkaloidsPapavarineInhibits HIV replication *in vitro* and reduces HIV protein production*Papaver somniferum* L. (Papaveraceae)([@bib105])CoumarinsSuksdorfinInhibits HIV replication*Lomatium suksdorfii* (S. Watson) J.M. Coult.&Rose (Apiaceae)([@bib54], [@bib105])FlavonoidsQuercetin 3--0-(2-galloyl) α-L arabinopyranoseAnti-HIV-1 integrase activity*Acer mono* Maxim (Sapindaceae)([@bib48])SaponinsEscinModerate anti-HIV-1 protease activity*Aesculus chinensis* Bunge (Sapindaceae)([@bib48])PhenolicsGallic acidExhibits HIV integrase and reverse transcriptase activity*Terminalia chebula* Retz. (Combretaceae)([@bib108])QuinonesConocurvoneShowed potent anti-HIV activity*Conospermum incurvum* Lindl. (Proteaceae)([@bib27])LignansDemethoxyepiexceisinGood anti-HIV activity in vitro*Litsea verticillata* Hance (Lauraceae)([@bib41])

Known compounds with anti-HIV activity include chloroquine, genistein and strictinin. Chloroquine, a 9-aminoquinoline, has a range of antiviral effects varying from the endocytosis to the exocytosis of viral particles, and, in addition, down regulates IFN-g and TNF-a production and TNF-receptors. It has shown activity against HIV-1, SARS coronavirus, human coronavirus OC43 and EBOV infection in vivo in newborn mice ([@bib26]). Strictinin and green tea catechins are active against the Influenza virus, Herpes simplex and HIV-RT ([@bib85]) and genistein inhibits arenaviral hemorrhagic fever infection in vitro ([@bib103]). *Citrus limon* (lemon) ([@bib51]), *Psidium guajava* (guava) ([@bib60]), *Ricinus communis* (castor oil) ([@bib10]), *Zingiber officinalis* (ginger) ([@bib31]), *Mangifera indica* (mango) and *Cocos nucifera* (coconut) are all examples of commonly used food plants with proven anti-viral activity.

Often a specific genus is identified with activity against a microorganism. The Amaryllidaceae is known for their alkaloid compounds, of which many have been identified with anti-viral activity. The major group of secondary metabolites occurring in the Amaryllidaceae is isoquinoline alkaloids with various structural variations ([@bib75]). Lycorine, narciclasine and pretazettine are well known compounds isolated from this family. Narciclasine inhibits protein synthesis at the step of peptide bond formation whereas pretazettine strongly inhibits the activity of RNA-dependent DNA polymerase (RT), from various oncogenic viruses by binding to the enzyme ([@bib32]). Other important compounds known to treat other ailments from this family include crinine and galanthamine with central nervous system activity due to their resemblance to morphine and codeine skeletons ([@bib32]). Studies on a specific family such as the Amaryllidaceae might also yield novel mechanisms and compounds for the treatment of HIV and can be a directed research focus in the search for anti-viral agents.

5. Inventory of medicinal plant species {#s0025}
=======================================

Medicinal plants with proven anti-HIV properties usually have other medicinal values, which may be an indication for these to be used as new drugs against the virus and its commonly associated infections ([@bib5]). [Table 3](#t0015){ref-type="table"} provides a summary of plants investigated from southern Africa and where present, the compounds that have been isolated, the activity and the possible mode of action of the compounds indicates the specific uses of the medicinal plants to treat HIV.Table 3An inventory of plants from the southern African region with anti-HIV activity, presenting their distribution, traditional uses, assays and results of the assays obtained.Table 3**Plant speciesDistributionTraditional useModel/ControlActive constituentsMode of actionPharmacological activity/Concentration rangesReference***Acacia brevispica* Harms (Leguminosae)Widespread in Africa, found in Sudan, Ethiopia, Somalia, Kenya, Zaire, Angola and South AfricaTraditionally used to treat infectious diseasesTetrazolium based colometric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). Azidothymidine (AZT) as positive control.None tested, coumaric and ferulic acid, quercetin, kaempferol isoquercitrin and hyperin present.HIV-1, 80% methanol leaves extract IC~50~ = 64.8 µg/ml and water extract IC~50~= 60.4 µg/ml.([@bib61], [@bib62], [@bib73])HIV-2 Water extract of shoots IC~50~ = 88.7 µg/ml.*Acacia tortilis* (Forssk.) Hayne (Leguminosae)Senegal, Nigeria, Sudan, Kenya, Tanzania, Israel, Jordan, Arabian Peninsula, Southern Africa and Namibia.Traditionally used to treat infectious diseases, vermifuge, skin infections, edema and allergic dermatoses.Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.HIV-1 80% methanol stem bark extract IC~50~ = 8.5 µg/ml and water extract IC~50~ = 4.2 µg/ml.([@bib61], [@bib62])HIV-2 80% methanol stem bark extract IC~50~ = 23.6 µg/ml.*Adansonia digitata* L (Bombaceae)Endemic to Africa.Antimicrobial, anti-malarial, diarrhea, anemia, asthma, antiviral, anti-oxidant and anti-inflammatory.HIV-RT colorimetric ELISA assay, HIV-1 PRVarious flavonoid glycosides and proanthocyanidin compounds in the leaves and the epicatechin compounds in fruit pulp.HIV-1 RT([@bib83], [@bib86])HIV-FRET and a recombinant HIV-1 protease solution. Nevirapine as positive control.Root bark extract 26.5% and 12.2% leaf extract inhibition at 50 μg/ml. Fruit pulp extract (100 μg/ml) 5.9% inhibition. Nevirapine (100 nM) 27.5% inhibition.HIV-PRLeaf extract and fruit pulp extract (50 μg/ml) 75% and 74% inhibition respectively.Root bark extract 35% inhibition.*Alepidea amatymbica* Eckl.&Zeyh. (Apiaceae)Widely distributed in southern Africa from the eastern Cape northwards to eastern ZimbabweColds, coughs, rheumatism, HIV, wounds and to wash divining bones.A cell-based assay targeting the replication of prototypic CXCR4-tropic (NL4--3) or CCR5-tropic (NL-AD87) HIV-1 strains. Positive and negative controls included in the assay.Rosmarinic acid and caffeic acid.Compounds bind to the catalytic core of purified HIV-1 integrase and blocks both activities of this enzyme.EC~50~ of aqueous extract at 22 μg/ml against the HIV-1 strain NL4--3 and 85 μg/ml against NL-AD87.([@bib13]; [@bib57])*Artemisia afra* Jacq. ex Willd. (Asteraceae)Kenya, Tanzania, Uganda, north to Ethiopia and south to South Africa and Namibia.Perfume, treat smallpox, infectious diseases and stomach ache. Anti-HIV for *A. annua*, but not *A. afra*.HIV-1 (IIIB) and HIV-2 (ROD) tested. Efavirenz (EFV) as control and *Aspalathus linearis* as negative drug.Many volatile and non-volatile compounds.Tea infusion IC~50~ = 2.0 µg/ml.([@bib5], [@bib56], [@bib58])A validated cellular system by testing each sample at various dilutions in triplicates.Extract against HIV- 1 and HIV-2 EC~50~ of\>123.5 µg/ml.*Aspilia pluriseta* Schweinf. (Compositae)DRC, Burundi, Rwanda, Uganda, Kenya, Tanzania, Malawi, Mozambique, Zambia, Zimbabwe and South AfricaTraditionally used for infection and rheumatic diseases, fevers and malaria.HIV (strain HTLV-IIIB/LAI) evaluating cytotoxicity and viral cytopathic effect.Thiarubrine-A, a dithiacyclohexadiene polyacetylen from the leavesTarget the interaction between the viral envelope glycoprotein gp120 and the CD4 receptor. The virus adsorp to the cells, but also virus-induced syncytium (giant cell) formation is inhibited. In addition, sulfated polysaccharides may also directly interfere with the binding of HIV particles to the heparin sulfate proteoglycan of the cell surface.Ethanolic extract EC~50~ = 16.3, SI\>12 with complete protection.([@bib23])*Bersama abyssinica* Fresen. (Melianthaceae)From Guinea Bissau through the coastal countries of West Africa except Benin, east to Eritrea and Ethiopia and south to Angola, Zambia, Zimbabwe and MozambiqueA purgative to treat abdominal pain, colic, diarrhea, cholera, intestinal worms, amoebiasis, dysentery, rabies, syphilis, gonorrhea and malaria, cancer, rheumatism, as an aphrodisiac, diabetes mellitus, feverish pains, loss of appetite, debility, jaundice, leprosy, burns, ulcers, wounds, convulsions, snakebites, migraine, headache, colds, hemorrhoids and epilepsy.HIV-RT colorimetric ELISA kit with Doxorubicin as positive control and the cytotoxicity and antiviral activity assays based on evaluating cell death caused by plant extract toxicity and inhibition of viral cytopathic effect with HIV-I (III~B~) and HIV-2 (ROD).The stem bark contain 2 bufadienolides, which are cardiac glycosides, sterols and mangiferin.Methanol extracts of leaves, bark and root inhibition of 89.17%, 85.11% and 95.21% respectively at 200 µg/ml with IC~50~ of 11.95, 18.75 and 9.38 µg/ml. Methanol root bark SI of 3.8 against HIV-1.([@bib5], [@bib65])*Boerhavia coccinea* Mill. (Nyctaginaceae)South-eastern United States, Africa including Namibia and South Africa, Asia, Australia, and South America.Traditionally used to treat infectious diseasesTetrazolium based colometric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.Boeravinone A, Boeravinone B, Boeravinone C, Coccineon B, Coccineon C, Coccineon D, Coccineon AHIV-1, 80% methanol shoot extract IC~50~ = 54.8 µg/ml and water extract IC~50~= 37.1 µg/ml.([@bib61], [@bib62], [@bib79])*Boerhavia erecta* L. (Nyctaginaceae)Native to the United States, Mexico, Central America and western South America, but now cosmopolitan in tropical and subtropical regions. In Africa its distribution extends from West Africa, eastwards to Somalia and down to South Africa. In Asia, it occurs in India, Java, Malaysia, the Philippines, China and the Ryukyu Islands.Traditionally used to treat infectious diseasesHIV-1 IN assayProcyacanidin, catechin, epicatechin, quercetin, kaempferol and isorhamnetin glucosides present.HIV-IN([@bib79], [@bib92])Quercetin-3-O-rutinoside IC~50~ = 10 µg/ml and isorhamnetin-3-O-rutinoside IC50 = 22 µg/ml isolated from stem bark.*Bridelia micrantha* (Hochst.) Baill. (Euphorbiaceae)Native to most of sub-Saharan Africa except South Africa and Namibia.HIV, diarrhea, sore eyes, stomach aches and abortifacient.HIV-1 RT. Isolated compounds also evaluated on HIV-1 IN.ß-sistosterol and friedelin isolated from roots.Ethyl acetate fraction of roots IC~50~ = 7.3 μg/ml. No effect on HIV-1 IN.([@bib9])*Bulbine alooides* (L.) Willd. (Asphodeliaceae)Distribution not well documented, occurs in South Africa.Burns, cracked lips, diarrhea, herpes simplex, itching, skin rash, ringworm, vomiting, HIV and wounds.HIV-1 p24 antigen assay.HIV-1 PR Tannin- dereplicated ethanol extract IC~50~ = 94.3 µg/ml. Ritonavir IC~50~ = 5.3 ng/ml([@bib34], [@bib50], [@bib64])HIV-1 RT, positive control nevirapine. The HIV-1 PR assay, HIV-FRET and a recombinant HIV-1 protease solution. Positive control pepstatin and ritonavir.*Cassia abbreviata* Oliv. (Caesalpiniaceae)Widespread in Africa, from Somalia to South Africa.Backache, abdominal pains, diarrhea, constipation, tooth ache, fever, ulcers, STI\'s such as syphilis and gonorrhea. Root and bark used as a general blood cleanser, appetite enhancer and reducing HIV levels.HIV-1c (MJ4) p24 antigen assay with AZT as positive control. Therapeutic index determined by neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells using the Spearman-Karber formula and by the End point titration technique with acyclor as positive control.*Cassia* roots contains anthocyanin, anthra- noids, anthraquinones, polyphenols and tannins.Ethanolic root extract EC~50~ = 102.8 μg/ml.([@bib55], [@bib104])P24% inhibitionTannin-containing = 55.1% and tannin-free = 38.5%.Methanol leaf and root extracts therapeutic index of 7.5 and 15 respectively and EPTT of 10^3^ for the root.*Centella asiatica* (L.) Urb. (Apiaceae)It is native to wetlands in Asia, but due to its invasive nature now found world-wide including southern Africa.Used to treat various diseases, such as gonorrhea, syphilis, diabetes, fever, leprosy, wound healing, gastro-intestinal ailments, HIV, asthma and neurosis.Contains various essential oils, asiatic acid, asiaticoside, madecassic acid, terminolic acid, quercetin, kaempferol and luteolin. Also phenylpropane and acetate metabolites.Immunomodulatory effect of aqueous or alcoholic extract.Asiatic acid and an anti-HIV agent with IC~50~ of 36 and 8 μg/ml.([@bib12], [@bib53], [@bib109])*Combretum adenogonium* Steud. ex A.Rich (Combretaceae)Widespread in Africa to the south in Botswana and Zimbabwe.Traditionally used to treat infectious diseases.Tetrazolium based colorimetric VSV T2 inhibition assay. AZT as positive control.Flavonoids, tannins, saponins, phytosterols, sitosterol and stigmasterol.HIV -- 1([@bib44], [@bib63])80% methanol leaf extract IC~50~ = 2.7 μg/ml and water = 4.8 μg/ml.80% methanol stem bark extract IC~50~ = 4.4 μg/ml and water = 5.6 μg/ml.HIV-280% methanol stem bark extract IC~50~ = 23.9 µg/ml and water =\>67.5 μg/ml.*Combretum molle* R.Br. ex G.Don (Combretaceae)Wide distribution, from Saudi Arabia, Yemen and Ethiopia, to South Africa in the south and westwards to West Africa, DRC and Angola.HIV, abdominal pains, snake bites, leprosy, fever, convulsions and Hookworm infection.HIV-1 RT. Isolated compounds were additionally evaluated on HIV-1 IN.Tannin, ellagitannin, pentacyclic triterpene glucosides namely punicalagin, arjunglucoside and sericoside.Inhibit RNA-dependent-DNA polymerase activity of HIV-1 RTIC~50~ = 37.5 µg/ml (water) and 9.5 µg/ml (methanol) against RDDP and IC~50~ of 13.7 µg/ml (water) and 9.7 µg/ml (methanol) against RNase H.([@bib10], [@bib44])*Combretum paniculatum* Vent. (Combretaceae)West Africa, east to Ethiopia, south to Angola, Mozambique and South Africa.Eye diseases, infectious diseases and leprosy.Cytotoxicity and antiviral activity assays based on evaluating cell death caused by plant extract toxicity and inhibition of viral cytopathic effect with HIV-I (III~B~) and HIV-2 (ROD).Pheophorbide a, pheophorbide, cardamonin, pinocembrin, quercetrin and kaempferol.Acetone leaf extract SI of 6.4 and 32.0 for HIV-1 and HIV-2 and the methanol extract with SI of 4.7 for HIV-1.([@bib5])*Dichrostachys cinerea* (L.) Wight&Arn. (Leguminosae)Native to Africa, Indian subcontinent and North Australia and introduced to the Caribbean and parts of Southeast Asia.Headache, toothache, dysentery, elephantiasis, leprosy, syphilis, coughs, as an anthelmintic, purgative epilepsy, diuretic and laxative.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).Friedelin, friedlan-3-ol, sitosterol and amyrin, octacosanol, hentricontanol, coumarins imperatorin, marmesin and aesculetinTherapeutic index of 7.5 for leaf and 3.7 for root methanol extract.([@bib104])*Dodonaea angustifolia* L.f. (Sapindaceae)Southern Africa to Arabia, as well as in Australia and New ZealandColds, influenza, measles, sore throat, oral thrush, stomach ailments, fever, itchy skin, rheumatism, hemorrhoids, pneumonia, tuberculosis and skin rashes.HIV-1 (IIIB) and HIV-2 (ROD) infected MT-4 cell lines. MTT colorimetric assay used for evaluation.Pinocembrin, santin, 2-hydroxy-15,16-epoxyceloda-3,13(16),14-trien-18-oic acid, 5,7,4\'-trihydroxy-3,6-dimethoxyflavone, ent-16-hydroxy-labdan-3α,8β-dihydroxy,13(14)-en-15,16-olide and 5,6,7-trihydroxy-3,4\'-dimethoxyflavone.HIV-1([@bib5])Leaf acetone and methanol extract EC~50~ of 27.7 and 21.3 µg/ml and SI of 3.9 and 4.9 respectively.*Elaeodendron croceum* (Thunb.) DC. (Celastraceae)South Africa and eastern escarpment of Zimbabwe.Similar species *E. transvaalensis* used for HIV.Recombinant HIV strain in an MT-2 VSV-pseudotyped recombinant virus assay.Digitoxigenin-3-O-glucoside, 4'-O-methyl epigallocatechin dimethyl-1, 3, 8, 10-tetra-hydroxy-9-methoxy-peltogynan, canophyllol, 30-hydroxylup-20(29)-en-3-one, 30-Hydroxylupeol, tingenin B, tingenone, galacticol, ouratea proanthocyanidin, ouratea proanthocyanidin-nona-O-acetate.VSV-pseudotype HI virus inhibition. Extract active at 100 ng/ml. Pure compound 90% inhibition at 0.2 µM.([@bib4]; [@bib82])*Elaeodendron schlechterianum* (Loes.) Loes. (Celastraceae)Widespread in the southern and tropical east African countries of Kenya, Tanzania, Mozambique, Malawi, Zambia and Zimbabwe.Traditionally used to treat infectious diseases.HIV-1 RT. Isolated compounds were additionally evaluated on HIV-1 IN and viral proteins (NF-κB and Tat). Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strainCardiac glycosides and tannins namely 4'-O-methylepigallocatechin, 4'-O-methylgallocatechin, 4',4''-di-O-methyl-prodelphinidin B4 or 4'-O- methylgallocatechin-(4α→8)-4'-O-methylepigallocatechin. ROD). AZT as positive control.HIV-1, 80% methanol stem bark extract IC~50~ = 7.1 µg/ml and water extract IC~50~= 28.7 µg/ml.([@bib4]; S. M. Maregesi et al., 2010)80% methanol root bark extract IC~50~ = 5.4 µg/ml and water extract IC~50~= 66.3 µg/ml.HIV-280% methanol leaves extract IC~50~ = 16 µg/ml.80% methanol stem bark extract IC~50~ = 11.1 µg/ml and water extract IC~50~= 46.8 µg/ml.80% methanol root bark extract IC~50~ =8.7 µg/ml.Potent inhibitory activity in both the NF-κB and Tat assays with inhibitory activity of 76% and 75%. No activity of pure compounds.*Elaeodendron transvaalense* (Burtt Davy) R.H.Archer (Celastraceae)Widespread in southern Africa, including Namibia.HIV, colds, skin rashes, fever, candidiasis, dysmenorrhea and stomach ache.HIV-1 RT. Isolated compounds were additionally evaluated on HIV-1 IN and viral proteins (NF-κB and Tat). Mesuol as positive control.3-Oxo-28-hydroxylbetuli-20(29)-ene and 3,28-dihydroxylbetuli-20(29)-eneIC~50~ of 80 µg/ml (water) and 131 µg/ml (methanol) against RDDP and IC~50~ of 31.2 µg/ml (water) and 30 µg/ml (methanol) against RNase H.([@bib4]; [@bib10]; [@bib71]; [@bib97])Chloroform and ethyl acetate extracts 64% and 76% inhibition respectively (1 µg/ml) in the NF-κB assay. Chloroform and ethyl acetate extracts\>70% inhibition at 15 µg/ml.*Elephantorrhiza goetzei* (Harms) Harms (Leguminosea)Wide distribution in south central Africa.Pain, sores, sexually transmitted infections (STIs), gastro-intestinal disorders, microbial infections and genito-urinary system disorders.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).Phenolic compounds, coumarins, flavonoids, saponins, stilbenoids, tannins and triterpenoids from bark, leaves and roots.Methanol root extract therapeutic index of 1.9.([@bib104])*Emilia coccinea* (Sims) G.Don (Compositae)Native to DR Congo, Burundi, Sudan, Kenya, Uganda, Tanzania, Malawi, Zambia, Angola, Zimbabwe and Mozambique.Traditionally used to treat infectious diseases, ulcers, craw-craw, ringworm, fever and convulsions in children.Tetrazolium based colometric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.Alkaloids, phenolics, flavonoids terpenoids and cardiac glycosides.HIV-1([@bib28], [@bib61], [@bib62])80% methanol shoot extract IC~50~ = 73.7 µg/ml and water = 27.9 µg/ml.*Euphorbia hirta L.* (Euphorbiaceae)Worldwide distribution. Very common in pan-tropic and partly subtropic areas including China, India, Philippines, Australia, Africa and Malaysia.Traditionally used to treat infectious diseases, female disorders, respiratory ailments, cough, coryza, bronchitis, asthma, worm infestations in children, dysentery, jaundice, pimples, gonorrhea, digestive problems and tumors.HIV-1 RT. The cytotoxic effect was measured by means of the colorimetric MTT assay.Alkanes, triterpenes, phytosterols, tannins, polyphenols and flavonoids.Inhibits HIV-1, 2 reverse transcriptase.([@bib37])Dose-dependent inhibition ofRT on HIV-1, HIV-2 and SIVmac251 IC~50~ = 38, 22 and 177 μg/ml respectively.Aqueous and 50% methanolic extracts HIV-1,2 activity with IC~50~ = 9 μg/ml and 5 μg/ml.*Euphorbia tirucalli* L. (Euphorbiaceae)Wide distribution in Africa, in northeastern, central and southern Africa.Traditionally used to treat infectious diseases, cancer, tumors, warts asthma, cough, earache, neuralgia, rheumatism, toothache,Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strainMany compounds such as euphol, euphorbin and tirucallinHIV-1([@bib61], [@bib62])ROD). AZT as positive control.Water extract (root) IC~50~ = 23.9 μg/ml.HIV-2Water extract (root) IC~50~ = 56.2 μg/ml.*Ficus sycomorus* L. (Moraceae)Native to Africa also grows naturally in Lebanon, Cyprus, Madagascar and naturalized in Israel and Egypt.Traditionally used to treat infectious diseases.Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.Various volatile compoundsHIV-1([@bib61], [@bib62], [@bib63])80% methanol stem extract IC~50~ = 8.3 µg/ml and water extract IC~50~= 37.6 µg/ml.HIV-280% methanol stem bark extract IC~50~ = 16.1 µg/ml and water extract IC~50~= 107 µg/ml.*Flacourtia indica* (Burm. f.) Merr. (Salicaceae)Tropical Africa south to northern South Africa, Swaziland, Madagascar, India, Sri Lanka, Indonesia and ChinaSnakebite, arthritis, STI, cough, pneumonia, and bacterial throat infection.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).Phenolic glycosides, lignin, β-sitosterol, polysaccharides, flavonoids, condensed tannins, alkaloids, terpenoids, sugars, coumarin such as scoparone and aesculetin, also flacourtin, pyrocatechol, homaloside D, poliothrysoside, β- sitosterol, β-D-glucopyranoside, ramantoside&butyrolactone lignan disaccharides.Methanol leaf and root extract therapeutic index of 0.9 and 1.3 respectively. Root RF of 10^3^.([@bib80], [@bib104])*Gymnosporia senegalensis* (Lam.) Loes. (Celastraceae)Sub-Saharan Africa from Senegal to Eritrea and south to northern Namibia, Botswana and South Africa. Also found in southern Spain, North Africa, Afghanistan to India, Aldabra and Madagascar.Gastro-intestinal troubles, schistosomiasis mouthwash for toothache, tooth-abscesses and mouth-infections, sores, eye-trouble, gastric ulcers, tertiary syphilis, female complaints, leprosy, dysentery and Blennorrhea.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).The leaves and branches contain dulcite and tannins. The leaves contain sterol, flavonol, slavonic glycoside, saponosides, flavone derivatives and tannins.Methanol extracts of leaf, root and twigs therapeutic index of 3.8, 3.8 and 1.2 respectively and RF of 10^3^ for all extracts.([@bib104])*Helichrysum spp.* (30) investigated with the highest activity in *Helichrysum populifolium*Most species occur in Africa, including Madagascar, South Africa and Namibia, also Southern Europe, south-west Asia, southern India, Sri Lanka and Australia.Coughs, colds, fever, infection, headaches, menstrual pain, HIV and wound dressing.The reporter cell line HeLa-SXR5, stably expresses the CD4 receptor and the CXCR4/CCR5 chemokine receptors DeCIPhR method on a full virus model.Di- and tricaffeoylquinic acids; 3, 4 dicaffeoylquinic acid; 3, 5 dicaffeoylquinic acid and 4,5 dicaffeoylquinic acid.Extracts tested at 25 and 2.5 μg/ml.([@bib34], [@bib40])*Helichrysum populifolium* DC (Asteraceae).Efavirenz positive control and negative control PBS/5% DMSO.Anti-HIV IC~50~ = 12--21 µg/ml.*Hoslundia opposita* Vahl (Lamiaceae)Widespread in tropical Africa and south to South Africa.Traditionally used to treat infectious diseases, gonorrhea, cystitis, coughs, fever, wounds, convulsions, sores, mental disturbances, abdominal pains, snake bites and for the relief of swellings.Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.5,7-dimethoxy-6-methylflavone, hoslunddiol and euscaphic acid with 5,7-dimethoxy-6-methylflavone HIV- 1 RT activity of 52%, at 100 µg/ml.HIV-1([@bib61], [@bib62], [@bib74]; [@bib81])Leaves extract (water) IC~50~ = 14.8 µg/ml.HIV-2Leaves extract (water) IC~50~ = 17.4 µg/ml.*Hypoxis hemerocallidea* Fisch., C.A.Mey.&Avé-Lall. (Hypoxidaceae)Native to southern Africa from South Africa as far north as Mozambique and Zimbabwe.Headaches, stomach ailments, dysentery, dizziness, burns, cancer, HIV, symptoms of benign prostrate hypertrophy, diabetes, high blood pressure, pimples, wounds, skin rush, dermatitis, mental disorders and general tonic for good health.HIV-1 RT assay and the therapeutic index determined by neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells using the Spearman-Karber formula and by the End point titration technique with acyclor as positive control. Determined the reduction factor (RF).Phytosterolglucosides (β-sitosterol), diglucoside hypoxoside, aglycone rooperol, sterols and sterolins.Remarkably stable CD lymphocyte counts concurrently with the decrease in serum p24 HIV antigen and expression of the HLA-DR CD8 lymphocyte activation marker on HIV patients. Show interference with the efflux of nevirapine across intestinal epithelial cells and potentially increase the bioavailability of this anti-retroviral drug when taken concomitantly.Inhibit HIV-1 RT. Methanol extract of tuber therapeutic index of 15 and RF of 10^3^.([@bib34], [@bib77], [@bib104])*Hypoxis sobolifera* Jacq.(Hypoxidaceae)Endemic to South AfricaTraditionally used directly in HIV/AIDS or symptoms/conditions closely associated with this disease.HIV-1 RT and PR assay.≥50% inhibition of HIV-1 RT and HIV-1 PR. Aqueous and ethanolic extracts inhibition at 0.2 µg/ml against HIV-1 RT.([@bib50])*Kigelia africana* (Lam.) Benth. (Bignoniaceae)Throughout tropical Africa and to the south in South Africa, Namibia and Swaziland. Introduced as an ornamental to Cape Verde, Madagascar, Iraq, Pakistan, India, China, South-East Asia, Australia, Hawaii and Central and South America.Traditionally used to treat infectious diseases, HIV, fainting, anemia, sickle-cell anemia, epilepsy, respiratory ailments, hepatic and cardiac disorders, and nutritional illnesses such as kwashiorkor, rickets, wasting, leprosy, impetigo, and worm infestations in the blood.Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control. Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).Various naphthoquinones, iridoids, sterols, coumarins, flavonoids and alkaloids kigelin, β-sitosterol, 1,3-dimethylkigelin and ferulic acid have been isolated from the bark, quercetinHIV-1([@bib6], [@bib61], [@bib62], [@bib84], [@bib85], [@bib104])([@bib53])Stem bark water extract IC~50~ = 83.2 µg/mlFruit6.93% RT inhibition at 100 µg/ml and 5.21 at 50 µg/ml.Leaves33% RT inhibition at 100 µg/ml and 11.3 at 50 µg/ml.Therapeutic index of methanol extract of bark and fruit of 1.2 for both and 10^3^ and 10^4^ RF values respectively.*Lannea schweinfurthii* Engl. (Anacardiaceae)Kenya, Uganda, Tanzania, Zanzibar, Malawi, Mozambique, Zambia, Zimbabwe, Swaziland and South Africa.Treatment of infectious diseases.Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.HIV-1([@bib61], [@bib62])80% methanol stem bark extract IC~50~ = 7.1 µg/ml and water extract IC~50~= 53.2 µg/ml.HIV-280% methanol stem bark extract IC~50~ = 9.9 µg/ml and water extract IC~50~= 89.4 µg/ml.*Leonotis leonurus* (L.) R.Br. (Lamiaceae)Native to southern Africa.Fevers, headaches, coughs, dysentery, remedy for snake bite and charm to keep snakes away.HIV-1 p24 antigen assay.No anti-HIV compounds, contains sterols, diterpenes, triterpenoids, tannins, flavonoids, alkaloids, quinines and saponins.Tannin-dereplicated ethanol extracts HIV-1 PR inhibition IC~50~ = 120.6 µg/ml. Ritonavir control IC~50~ = 5.3 ng/ml([@bib34], [@bib50])HIV-1 RT. Positive control nevirapine. HIV-1 PR assay, HIV-FRET and a recombinant HIV-1 protease solution used.Positive control for HIV-1 PR acetyl pepstatin and ritonavir.*Leonotis nepetifolia* (L.) R.Br. (Lamiaceae)It is native to tropical Africa and southern India, Latin America and the West Indies.Traditionally used to treat infectious diseases and HIVTetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.Ethanolic extract cytotoxic with SI\<1 against HIV-1.HIV-1([@bib23], [@bib53], [@bib61], [@bib62])HIV (strain HTLV-IIIB/LAI) evaluating cytotoxicity and viral cytopathic effect.80% methanol leaves extract IC~50~ = 32.8 µg/ml and water extract IC~50~= 34.9 µg/ml.HIV-280% methanol leaves extract IC~50~ = 119 µg/ml.*Lobostemon trigonus* (Thunb.) H.Buek (Boraginaceae)Endemic to South AfricaDecoction for wound healing, ulcers and ringworm or as an infusion for blood purification.HIV-1 RT assay and HIV-II PR assay.The genus is known to contain naphthoquinone derivatives, pyrrolizidine alkaloids, cyclitols, phenolic acids, tannins and the ureide allantoinAqueous extract of leaves HIV-1 RT activity at IC~50~ = 49 µg/ml. No HIV-II PR activity.([@bib38])*Myrothamnus flabellifolia* Welw. (Myrothamnaceae)South Africa, Angola, Botswana, Madagascar, Zimbabwe, Mozambique, Malawi, Tanzania, Namibia, Zambia and Kenya.Treatment of chest complaints (smoke of burning leaves), wounds (in ointments for topical application), and to treat cough, influenza, mastitis, backaches, kidney disorders, hemorrhoids, abdominal pains, scurvy, halitosis and gingivitis.HIV-1 RT assay.Polyphenolic compounds and 3, 4, 5 tri-O-galloylquinic acid. Pinocarveol, pinocarvone, and β-selinene are the most abundant volatiles, along with α-pinene, limonene, and a few other terpenoids.Abolished virus entry into the host cell by blocking viral attachment to the cell surface. Directly interacted with viral particles, leading to the oligomerisation of envelope proteins as demonstrated for the essential viral glycoprotein D (gD).Inhibition non-competitive, with IC~50~ for 3, 4, 5, tri-O-galloylquinic acid of 5 μM for M-MLV and 34 μM for HIV-1.([@bib35], [@bib36], [@bib68])*Ozoroa reticulata* (Baker f.) R. Fern.&A. Fern (Anacardiaceae)Widely distributed from southern Ethiopia, Zaire to southern Africa.Traditionally used to treat infectious diseases, kidney and liver complaints, chest pain, diarrhea, schistosomiasis, ulcers and hernias, otitis, colic, dysentery, muscle pains, fever, hypertension and throat infections.Tetrazolium based colorimetric assay using HIV-1 (strain III b) and HIV-2 (strain ROD). AZT as positive control.6-pentadecylsalicylic acid, toxic to brine shrimp and anacardic acid and ginkgoic acid as cytotoxic components.HIV-1([@bib61], [@bib62])Leaves 80% methanol = 16.2 µg/ml and water = 81.4 µg/ml.Stem bark 80% methanol = 11.6 µg/ml and water = 15.8 µg/ml.Root bark 80% methanol = 20.6 µg/ml*Pelargonium sidoides* DC. (Geraniaceae)Native to South Africa and Lesotho.Gonorrhea, diarrhea, dysentery, a prolapsed rectum and intisila*,* colic, wounds, acute bronchitis, cold, acute rhino sinusitis, influenza and herpes virus.Transfection with the proviral HIV- 1 plasmid. HIV-1 particles pseudotyped with the VSV protein. Positive controls AZT and Efavirenz.Gallic acid, umckalin, catechin, oleic acid, linoleic acid and coumarins.Interferes directly with viral infectivity and blocks the attachment of HIV-1 particles to target cells, protecting them from virus entry.HIV-1 attachment inhibitor with EC~50~ = 8.13 µg/ml. EC~50~ for gallocatechin-(4β-8)- gallocatechin 7.3 µg/ml, epigallocatechin-(4β-8)-gallocatechin 6.3 µg/ml, epigallocatechin 42.5 µg/ml and gallocatechin 28.4 µg/ml.([@bib39], [@bib70])*Peltophorum africanum* Sond.(Ceasalpiniaceae)Native from southern DR Congo to South Africa and Swaziland. Cultivated in Kenya, Tanzania, Madagascar, Australia and the United States.HIV, wounds, toothache, sore throat, cough, tuberculosis, abdominal disorders, diarrhea, dysentery, menorrhagia, infertility.HIV-1 RT assay. Isolated compounds were additionally evaluated on HIV-1 IN.Contains flavonoids and C-galloylglycosides namely (+)-catechin, bergenin and betulinic acid.Gallotannin inhibited RDDP and RNase H RT IC~50~ = 6.0 and 5.0 µM, respectively, and abolished the 3'-end processing activity of IN (100 µM). Bergenin no effect on IN (100 µM).([@bib10])Catechin no effect on RT, moderate activity on HIV-1 IN.HIV-~NL4--3~: Betulinic acid = 0.04 µg/ml, HIV-1~JRCSF~: Betulinic acid = 0.002 µg/ml.*Plectranthus barbatus* Andrews (Lamiaceae)Worldwide, found in sub-Saharan Africa as an invasive speciesAnti-spasmodic, gastric disturbances, malaria, candida, managing HIV/AIDS, and opportunistic infections, herpes simplex, herpes zoster and skin rashes.HIV-1 PR assay. Acetyl pepstatin (AP) was used as a positive control.Various compounds isolated including betulinic acid, caffeic acid, diterpenes and forskolin.PR activity could be attributed to diterpenoids.HIV-1 PR([@bib2], [@bib18], [@bib46], [@bib49])HIV-1 RT assay, doxorubicin as positive control.Ethyl acetate extract 70% inhibition at 100 µg/ml (IC~50~ = 62.07 µg/ml)Acetyl-pepstatin 97% at10 µg/ml and its IC~50~ was 0.3 µg/ml.HIV-1 RT50% inhibition.Doxorubicin, IC~50~ = 25 µg/ml.*Prunus africana* (Hook. f.) Kalkman (Rosaceae)Wide distribution in Africa, from central to South Africa and on the islands of Bioko, São-Tomé, and Grande Comore.Fevers, malaria, wound dressing, arrow poison, stomach pain, purgative, HIV, kidney disease, appetite stimulant and gonorrhea.HIV-1 RT assayFerulic acid, n-docosanol, lauric acid myristic acid, β-sitostenone and β-sitosterolStem bark ethanol extract % RT at 100 µg/ml = 99.2 and 50 µg/ml = 71.2([@bib34], [@bib45], [@bib84])*Rhus chirindensis* Baker f. (Anacardiaceae)Widespread in African from Tanzania in the north to the Cape in the south.Treating heart complaints, strengthen the body, stimulate circulation and treatment of rheumatism and mental disorders and sexually transmitted diseases.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF)Flavonoids and triterpenoids.Methanol root extract therapeutic index of 3.8.([@bib104])*Rumex bequaertii* De Wild. (Polygonaceae)Europe through Asia to China, Vietnam and Indonesia, Africa, mainly in the east from Eritrea and Somalia to South Africa.Traditionally used for infection and rheumatic diseases, purgative, rheumatism, colic, stomach-ache and abdominal pains, abscesses, schistosomiasis and headachesHIV (strain HTLV-IIIB/LAI) evaluating cytotoxicity and viral cytopathic effect, examined spectrophotometrically by the MTT-method.Emodin, chrysophanol, physcion, anthraquinones aloesin, rumexoside, orientaloside, torachrysone, nepodin, nepodin-8-O-β-D-glucopyranoside, torachrysone and torachrysone-8-O-β-D-glucopyranoside.Target the interaction between the viral envelope glycoprotein gp120 and the CD4 receptor. The virus adsorp to the cells, but also virus-induced syncytium (giant cell) formation is inhibited. Sulfated polysaccharides may also directly interfere with the binding of HIV particles to the heparin sulfate proteoglycan of the cell surface.Ethanolic extract EC~50~ = 17.69 with SI\>11% and 89% cell protection.([@bib23], [@bib102])*Sclerocarya birrea* (A. Rich.) Hochst. (Anacardiaceae)Widespread throughout the semi-arid deciduous savannas of much of sub-Saharan Africa.Hypertension, dysentery, stomachache, gastro-enteritis, anti-cough remedy, hypertension, antihyperglaecemic, diarrhea, dysentery, malaria, general tonic and sexually transmitted diseases.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).Phenolic compounds, proanthocyanidins, gallotannins and flavonoids such as quercetin 3-O-alpha-l-(5\' \'-galloyl)-arabinofuranoside.Methanol extract of bark therapeutic index of 1.9 and RF of 10^3^.([@bib104])*Securidaca longipedunculata* Fresen. (Polygalaceae)Tropical and subtropical areas of Africa with protected status in South Africa.Stomach complaints, tuberculosis,The anti-HIV and anti-SIV activities and toxicities of compoundsCaffeoylquinic acids: 3,4,5-tri -O-caffeoylquinicBinds irreversibly to gp120 and inactivates virus.EC~50~ for 3,4,5-tri-O-caffeoylquinic([@bib5], [@bib59], [@bib72], [@bib104])wound dressing, rheumatism, syphilis, cough, diarrhea, syphilis and typhus.assessed in C8166 cells infected with HIV-1 III-B,acid and 4,5-di-O-caffeoylquinic acid as well as Caffeic acid, rosmarinic acid and synapoic acid.acid HIV 1 and HIV 2 = 0.32 µg/ml and no activity, 4,5-di-O-caffeoylquinc acid at 0.6 and 8 µg/ml, caffeic acid at 0.16 µg/ml and no activity and synapoic acid at 200 and\>200 µg/ml. Rosmarininc acid 40 and 100 µg/ml.HIV-2 Rod or SIV MacCell viability of virus-infected and uninfected control.Methanol extract of root therapeutic index of 3.8 and RF of 10^3^.Evaluated by the MTI-Formazan method. AZT as control. Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).*Sutherlandia frutescens* (L.) R.Br. (Fabaceae)Endemic to southern AfricaHIV, relieving cold, influenza, chicken pox, diabetes, varicose veins, piles, backache, rheumatism, physical and mental stress.Non-radioactive HIV-RT colorimetricHigh levels of free amino acids, non-protein amino acids such as canavanine and GABA, cyclitol pinitol, flavonols and triterpenes including SU1.Canavanine is an inhibitor of nitric oxide synthase and has potential for the treatment of septic shock, a condition associated with advanced stages of AIDS.Leaves and flowers\>50% inhibition against HIV-1 RT. No HIV-II PR activity (≥50%) when assayed at 0.2 mg/ml.([@bib34], [@bib38], [@bib101])ELISA kit with fluorometric detection of HIV-II PR.*Terminalia mollis* M.A.Lawson (Combretaceae)Widespread in Africa occurring in West Africa, Angola, DR Congo, Uganda, Kenya, Tanzania, Zambia and Zimbabwe.Treatment of infectious diseases.Tetrazolium based colorimetric VSV T2 inhibition assay. AZT as positive control.Tannins and saponins.HIV-1([@bib61], [@bib62], [@bib63])80% methanol stem bark extract IC~50~ = 5.9 µg/ml and water extract IC~50~= 9.8 µg/ml.80% methanol root bark extract IC~50~ = 2.06 µg/ml and water extract IC~50~= 4.4 µg/ml.HIV-280% methanol stem bark extract IC~50~ = 13.6 µg/ml and water root bark extract IC~50~ = 16.4 µg/ml.*Terminalia sericea* Burch. ex DC. (Combretaceae)Endemic to Africa from Tanzania and the DR of Congo southwards to South Africa.Diabetes, diarrhea and STI.HIV-1 RT and viral proteins (NF-κB and Tat) assays. Reference drug Adriamycin. Mesuol as a reference inhibitor of NF-κB. Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor (RF).Triterpenoids, saponins, tannins and Anolignan BExtracts tested at 50 µg/ml and the active extracts were further tested at 25, 15, 5 and 1 µg/ml.HIV-1 RT([@bib29], [@bib97], [@bib104])IC~50~ = 43 µg/mlAdriamycin (IC~50~ = 100 µg/ml.No activity on NF-κB and Tat.Methanol extract of leave and roots with therapeutic index of 1.2 and 1.9 respectively.*Tithonia diversifolia* (Hemsl.) A.Gray (Asteraceae)Native to Mexico, Central America and Cuba, naturalized in tropical parts of Asia, Africa and Pacific islands.Traditionally used for infections, rheumatic diseases, ascariasis and diarrhea.HIV (strain HTLV-IIIB/LAI) evaluating cytotoxicity and viral cytopathic effect, examined spectrophotometrically by the MTT-method.Sulfated polysaccharides, polyphenolic compounds such as hydrolysable tannins, diversifolin, diversifolin methyl ether and tirotundin.Target the interaction between the viral envelope glycoprotein gp120 and the CD4 receptor. The virus adsorp to the cells, but also virus-induced syncytium (giant cell) formation is inhibited. In addition, sulfated polysaccharides may also directly interfere with the binding of HIV particles to the heparin sulfate proteoglycan of the cell surface. diversifolin, diversifolin methyl ether, tirotundinHIV-1([@bib23])They inhibited the DNA binding activity of the transcription factor NF-κB, resulting in a decreased production of inflammatory mediators, such as cytokines and chemokines.EC~50~ =\>1.60 µg/ml with SI\<1. Water sub-fraction EC~50~ = 0.04 µg/ml with SI\>461 with complete cell protection.*Vernonia amygdalina* Delile (Asteraceae)Wild in most countries of tropical Africa, from Guinea east to Somalia and south to north-eastern South Africa, and in Yemen.Traditionally used for infections, rheumatic diseases, ascariasis, hepatitis, malaria, diabetes, worms, tonsillitis, fever, STI, HIV, measles, skin problems and chicken pox.HIV (strain HTLV-IIIB/LAI) evaluating cytotoxicity and viral cytopathic effect, examined spectrophotometrically by the MTT-method.Gallic acid, chlorogenic acid, dicaffeoyl acids, quercetin, vernolide, octahydrovernodalin, vernonioside A3, vernodalol, vernomenin, vernolide, vernolepin, vernodalin and vernodalinol.HIV-1 inhibition EC~50~ =\>19.66 µg/ml.([@bib24], [@bib53], [@bib96])SI\<1.*Vernonia stipulacea* Klatt (Asteraceae)Zambia, Tanzania, Malawi, Mozambique, Zimbabwe; widespread in tropical Africa, extending to South Africa.HIV, diarrhea, fever, flu and contraceptive.HIV-1 RT assay and HIV-II PR assay.Weak HIV-1 RT activity at\>100 µg/ml.([@bib10])*Warburgia salutaris* (G.Bertol.) Chiov. (Canellaceae)Botswana, Namibia, Tanzania, Zambia, Mozambique, South Africa, Swaziland, Malawi and Zimbabwe.Malaria, respiratory complaints such as cold and cough and sexually transmitted diseases and HIV.Neutralization test to determine non-cytotoxic concentration (ID~50~) that inhibits/protects 50% of the monolayer cells against destruction by the virus compared to uninfected cells with acyclor as positive control. Determined the reduction factor.Muzigadial, 9B-Octahydro-6, 6, 9Atrimethylnaphtho\[1, 2c\] furan-1-(3H)-one (drimenin), 5, 10-Dihydro-6, 7-dimethyl-4H-benzo \[5, 6\] cyclohepta \[1, 2-b\]-furan, warburganal and polygodial.Methanol root extract therapeutic index of 1.2 and RF of 10^3^.([@bib53], [@bib104])*Zanthoxylum davyi* Waterm. (Rutaceae)Native to South Africa, western Swaziland and eastern Zimbabwe.Traditionally used in treatment of sexually transmitted diseases, chest pains, wounds, toothache, coughs, pleurisy, toothache, snakebites, heal sores, sore throat and aphrodisiac.HIV-1 RT and viral proteins (NF-κB and Tat).Benzo\[c\]phenanthridine alkaloids, chelerythrine, dihydrochelerythrine, bocconoline, 6-hydroxydihydrochelerythrine and 6-methoxy-7-demethyldihydrochelerythrine, together with 4-methoxy-1-methyl-2(1H)-quinolinone and the uncommon lignan meso-sesamin.70% acetone extract([@bib94], [@bib98])Mesuol as positive control.Nf-κB 54% inhibition at 15 µg/ml, Tat 50% inhibition at 15 µg/ml.*Ximenia americana* L. (Olacaceae)Tropical and temperate regions.Contagious diseases, stomach complaints, placenta expulsion, internal parasitism and worm infestations.HIV-1 (IIIB) and HIV-2 (ROD) infected MT-4 cell lines. MTT colorimetric assay used for evaluation.Proanthocyanidins and a triterpenoid saponin.Inhibits HIV-1 replicationHIV-1([@bib5])Senegal to Ethiopia and south to South Africa.Stem bark extractEC~50~ = 8.3--27.7 µg/ml and selectivityindices 3.9--4.9. Hydroalcohol extractEC~50~ = 8.3 µg/ml (HIV-1) and 27.1 µg/ml(HIV-2) with SI of 4.5 and 1.4 respectively.*Ziziphus mucronata* Willd. (Rhamnaceae)Botswana, Namibia-Caprivi, DR Congo, southern Tanzania, Mozambique, Zambia, South Africa and ZimbabweHIV, diarrhea, dysentery, stomach ulcers, fever, anti-peristalsis, skin diseases, anti-inflammatory, menorrhagia, infertilityHIV-1 RT assay and HIV-II PR assay.RDDP([@bib10])IC~50~ = 77.5 µg/ml (water) and 81.5 µg/ml (methanol) HIV-1 RT IC~50~\>100 µg/ml (water) and 75 µg/ml (methanol)

The distribution of each species is presented and the traditional use of the species therefore reflect the distribution of the species as it is strongly linked to the availability of a species in a region. Of the 56 plant species (excluding the group of *Helichrysum* species) documented in this study; 20 have reported popular use to treat HIV or HIV symptoms, 20 have been reported for treatment of infectious diseases and another 13 other anti-viral activity such as influenza and chicken pox, whereas the mode of action was scientifically reported in only 13 plants. The other 3 plants have been tested for anti-HIV activity based on similarity of plants with popular or tested anti-HIV or anti-viral activity such as *Elaeodendron croceum* (*E. transvaalensis* and *E. schlechterianum* with popular use for HIV and infectious diseases) and *Leonotis leonurus* (*L. nepetifolia* with popular use for HIV). The species that are similar to those commonly used for HIV have been included, as ethnobotanical documentation are often incomplete and species are often misidentified. The activity of "related" species might therefore be species that have also been commonly used to treat HIV or other viral infections, but not correctly identified or documented.

6. Phytochemistry of anti-viral components {#s0030}
==========================================

By analyzing and comparing the information on plants from the southern African region popularly used for HIV treatment, or tested anti-HIV activity, several compounds and compound groups have been repeatedly reported, and by evaluation of these compounds and compound groups, been classified into three distinct groups. The three groups identified are:-Flavonoids such as quercetin in *Vernonia amygdilana* and flavonoid glycosides in *Sutherlandia frutescens.*-Terpenoid and terpenoid glycosides such as sericoside in *Combretum molle,* betulinic acid in *Peltophorum africanum* including the cardiac glycosides found in the two Elaeodendrom species *E. croceum* and *E. schlechteranum*-The phenolic acids such as gallic acid, rosmarinic acid and caffeic acid from *Alepidea amatymbica* and their conjugated acids such as dicaffeoylquinic acids (DQCA) from *Vernonia amygdilana*, di- and tricaffeoylquinic acids (TCQA) from various Helichrysum species and trigalloylquinic acids (TGQA) from *Myrothamnus flabellifolius* and *Securidaca longipedunculata.*

Sufficient evidence for the antiviral activity of the phenolic acids has accumulated over the years and is still explored in many medicinal plant species ([@bib40]). Some of the dicaffeoylquinic acids (DCQAs) and the dicaffeoyltartaric acids (DCTAs) are selective inhibitors of HIV-1 IN at concentrations between 150 and 840 nM. The compounds that have been reported to date include 3,5-DCQA, 1-methoxyoxalyl-3,5-DCQA (1-MO-3,5-DCQA), 1,5-DCQA, 3,4-DCQA and 4,5-DCQA, as well as a related dicaffeoyltartaric acid (L-chicoric acid) ([@bib66]). Some of the caffeoyl- and galloylquinic acids is nonspecific in its anti-HIV activity and binds to the gp120 protein to inhibit virus replication, preventing binding to the CD4 receptor. They are also not specific to the HI virus as similar anti-viral activity was also observed with HSV type 1. The galloyl derivatives were previously shown to inhibit the in vitro activities of both HIV-RT and cellular DNA polymerases, in particular DNA polymerase a ([@bib59]). [@bib66], however, strongly argue that the activity of these compounds is not linked to HIV-RT, but that they are several times more active on the HIV IN enzyme. Some caffeoylquinic acids showed activity against HIV-1 IN, but caffeic acid and chlorogenic acid were not active, and show the selective nature of this wide variety of related compounds. Chlorogenic acid and quinic acid, which was not active on HIV-1 IN reduced the amount of HBV-DNA more effectively than that of the viral antigens ([@bib107]) also showing the potential use of the CQA\'s to treat other viral infection. The CQA\'s have been reported in numerous studies to have potent activity against HSV as well ([@bib47], [@bib52], [@bib67], [@bib95]). Furthermore, it was shown that very active and abundant anti-HIV compounds such as 5-O-chlorogenic acid (5-CGA) is highly bioavailable as it is absorbed in the stomach and jejunum followed by absorption along the small intestine and also the large intestine ([@bib30]). Other compounds such as 3-CQA, 5-CQA, 3,4-DCQA, 3,5-DCQA, and 4,5-DCQA are all present in the plasma with low concentrations of caffeic, ferulic, isoferulic, and p-coumaric acids ([@bib30]) and might not be realistically recorded in in vitro assays which are often reported at much higher concentrations.

Chlorogenic acids and other dihydroxycinammic acids such as caffeic acid have been described previously as anti-oxidants and therefore beneficial compounds. A more possible explanation is however their pro-oxidant activity as they can be oxidized to form quinones when oxidized by peroxidase/H~2~O~2~ or tyrosinase/O~2~. These quinones can be very toxic in cells due to creating oxidative stress, but are kept in their unoxidised state by antioxidants such as glutathione or ascorbic acid ([@bib69]). Flavonoids act as pro-oxidants in producing a quinone which produce reactive oxygen species (ROS) which are very effective in the defense of herbivores and pathogenic attack. Addition of 0.2% caffeic acid or 0.2% 5-CQA to mice, resulted in a significantly increased level of Glutathione S-transferase (GST), probably due to their pro-oxidant activity and electrophile-responsive element (EpRE) activation. Similarly many cinnamic acids have been shown to be potent inducers of NAD(P)H:(quinone-acceptor) oxidoreductase ([@bib20]). The DCQA\'s and DCTA\'s are bis-catechols and do not appear to inhibit HIV-1 RT within the cell, but acting directly through inhibition of IN ([@bib66]).

The mechanism of how the phenolic acids act on viruses to inhibit their replication or infection is however not well researched. Compounds such as 5-CQA and related chlorogenic acids have been tested numerously, not only to confirm their anti-HIV activity, but also their activity on HSV-1, HSV-2 and Adenovirus-11 ([@bib15]; [@bib66]; [@bib93]; [@bib95]; [@bib107]). This also supports the traditional or popular use of many of these plants for other viral infections, but showing potent anti-HIV activity when tested in vitro.

7. Discussion {#s0035}
=============

Poor nutrition, inaccessibility to health systems and overburdened health budgets and resources contribute to the spread and inadequate control and continued infection of HIV ([@bib22]). Many studies have relied on the traditional uses of medicinal plants in treating viral infections and various accounts of very active plants have been documented ([@bib10]). Where anti-HIV activity could be linked to isolated compounds from southern African plants, it is often compounds previously identified for anti-HIV activity in plants from other regions of the world. It is therefore evident that similar compounds or compound groups have been identified as the active principles in plant preparations from various regions in the world and the repeated identification should be supported by progression into in vivo studies, especially in the southern African region where affordable and safe medicines are needed urgently.

Plants continue to provide drug leads and numerous plants and/or plant compounds have been advanced to clinical trials (Yang et al., 2011). Enough evidence has been accumulated in various studies to warrant further investigation into the active principles and chemical profile of anti-viral plants with specific focus on the three mentioned groups. A systematic review by Liu and Yang (2005) assessed the beneficial effects and risks of herbal medicines in patients with HIV infection and AIDS, and concluded that there is inadequate evidence to support the use of herbal medicines in HIV-infected individuals and AIDS patients. However, potential beneficial effects need to be confirmed in large, rigorous trials (Liu et al., 2005). Few southern African plants or plant compounds are currently in clinical trial studies. For example, *S. frutescens,* indigenous to Lesotho, South Africa, southern Namibia and southeastern Botswana has a wealth of preclinical data ([@bib101]). A phase I study has shown that *S. frutescens* is well tolerated and that it showed no significant side effects (Johnson et al., 2007). Recently the results of an adaptive two-stage randomized double-blind placebo controlled study were published. The study evaluated the safety of consuming dried *S. frutescens* by HIV seropositive adults with CD4 T-lymphocyte count of\>350 cells/μL. *Sutherlandia frutescens* did not change HIV viral load, and CD4 T-lymphocyte count and was similar in the two arms at 24 weeks; however, mean and total burden of infection was greater in the *S. frutescens* arm attributed to two tuberculosis cases in subjects taking isoniazid preventive therapy (IPT). The study concluded that possible interaction between *S. frutescens* and IPT needs further evaluation, although no other safety issues relating to consumption of *S. frutescens* were identified (Wilson et al., 2015). The equally good activity of some of the compounds such as the chlorogenic acids on other viruses such as HSV also support intensified in vivo studies to support developing these plant extracts or compounds into anti-viral treatments. Apart from *S. frutescens* entering clinical studies, no other plants from this region have advanced to this stage, even though the majority of HIV infected individuals are treated with medicinal plant preparations from this region. The low number of plant extracts and compounds in advanced studies support the need for more focus on developing the research potential identified in the published studies to reach the commercial market. By evaluating and advancing more herbal preparations and compounds for testing in vivo will ensure that more treatments reach the commercial markets.

8. Conclusion {#s0040}
=============

Throughout the paper, evidence is presented which shows that although southern Africa possesses a wealth of medicinal plants, most of the research on the screening and isolation of active compounds was carried out only in vitro on enzymes and viral proteins, with no follow-up research to validate the results in vivo. This could be attributed to the lack of long term funding and infrastructure and is supported by many plants tested in facilities not within the southern African region. From screening literature, it would therefore seem as if common compounds or compound groups from southern African plants, of which many are well-known and previously confirmed for their anti-viral activity from plants from other areas of the world, are repeatedly identified as anti-HIV agents. It is therefore argued that the presence of well-known and well-researched plant compounds with anti-HIV activity from southern Africa should direct future focus in development of anti-viral agents for rapid development of affordable anti-HIV treatments. This should also be followed-up in in vivo studies as this information is lacking and anti-HIV activity is only dependent on the in vitro assay results currently available. In this review current information on southern African plants with traditional use against viral infections and specifically HIV treatment or HIV related diseases or symptoms is presented with the aim to develop treatments for people living with HIV/AIDS, as there is an urgent need to fast track in vivo testing and HIV/AIDS clinical trials of candidate drugs developed from compounds isolated from plants for effective and affordable alternatives to current treatment options.
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